Thu, Jul 10, 2014, 4:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celgene Corp. (CELG) Message Board

  • biocalender biocalender Jun 2, 1998 10:37 AM Flag

    Keep Buying

    Key Announcement At June 28 Annual Meeting Re Approval

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It would be wrong to presume that the news would
      be total remission. As there is no cure for this
      cancer. I do beleive the results will show a vast
      improvement in 30% of the patients which is better than
      anything else that has been done with this cancer. I
      believe the news will be exciting but it will not be
      total remission.

    • Cellgone writes <<Rob,I rarely post on this
      board but I do follow it. In regards to Dr. Barlogia, I
      am aware via a friend who works there that he is in
      the process of changing his myeloma protocals and
      replacing whatever chemo-drug he has been using as the
      intial drug therapy for all myeloma patients to
      Thalidomide.
      >>
      ***************************************************************
      THANKS FOR THE INFO CELLGONE- IF 25% OF THE FAR
      ADVANCED PATIENTS SAW "EXCITING" RESULTS AFTER RELAPSING
      AFTER TANDEM TRANSPLANTS, IT IS PROBABLY LOGICAL THAT
      WE WILL SEE EVEN BETTER RESULTS IF GIVEN IN THE
      EARLY STAGES OF THE DISEASE. I MEAN, LETS REALLY THINK
      ABOUT THIS DOCTOR, A PIONEER IN THE TREATMENT OF
      MULTIPLE MYELOMA, ABANDONING CONVENTIONAL CHEMO FOR
      THALIDOMIDE IN ALL OF HIS PATIENTS. BASED ON THIS I HAVE TO
      BELIEVE THAT THE "EXCITING" RESULTS HE HAS PUBLICALLY
      TALKED ABOUT MUST BE TOTAL REMSSION. DO NOT
      UNDERESTIMATE THE IMPACT THE RESULTS OF THIS TRIAL AND THE
      CROHNS TRIAL WILL HAVE. THE STOCK IS DOWN BUT THE
      COMPANY'S FUTURE HAS NEVER BEEN BRIGHTER. AND THALOMID IS
      ONLY THE TIP OFF THE ICEBERG.

    • but wont until the hype is over and the news prevails !

    • I always wanted in at this price; got in at 10. I
      remember posting a message when Thal was approved saying I
      hope it wasn't just a mometary blip. But if the
      overall market is back to 12/97 then whats the big
      deal.

      This stock has much going for it in the future; the
      only things in the present are the market and the name
      Thalidomide.

      Hold. Or add at bargain basement prices

    • OUCH!!!!! Today hurt but I am long and holding.
      hang tough and good luck!!!!
      CWCR

    • Don't let the shorts shake you out in a panic - DON'T sell a share - I believe there are such good things coming that we will rebound mightily once the news is out. DON'T SELL A SHARE!!!!!1

    • Would like to buy more Celgene at these
      prices.....
      HOWEVER, I am meeting a margin call
      now. Holding...not selling.

      GO Celgene>>>$$$UP
      NOT DOWN

    • Hi,

      Is anyone on this board buying more celg at these low 7 prices?

      I am too spooked to add now, but will hold.

    • Rob,I rarely post on this board but I do follow
      it. In regards to Dr. Barlogia, I am aware via a
      friend who works there that he is in the process of
      changing his myeloma protocals and replacing whatever
      chemo-drug he has been using as the intial drug therapy for
      all myeloma patients to Thalidomide. However I do not
      think the number of patients is that significant since
      they only treat probably 500 patients per year there.
      But I do agree with you that the press release on
      this will have a positive impact on the stock.

    • Don't let the shorts/overall market conditions
      get you down. The Crohns and Multiple Myeloma trial
      results will be released in the near furture. Read the
      Lancet article as well as the following excerpt
      mornapicks found on the internet:

      $+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+$+
      Here is an excerpt from an interview with Dr. Bart
      Barlogie of the University of Arkansas which appeared in
      the Summer 1998 edition of Myeloma Today. The full
      article is available on the internet.

      MT: What is
      your opinion about new and future
      treatments?

      Prof. Barlogie: Anti-angiogenesis therapy has received
      a lot of attention recently due to the pioneering
      work of Judah
      Folkman. We are investigating
      Thalidomide which presumably exerted its teratogenic effects
      by interfering with basic
      fibroblast growth
      factor, an important angiogenic molecule. Exciting
      results have been obtained in approximately a
      quarter
      of patients with far advanced myeloma, most of whom
      had relapsed from tandem transplants.

    • View More Messages
 
CELG
87.83+0.31(+0.35%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.